Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
14 hedge funds and large institutions have $117K invested in Vincerx Pharma, Inc. Common Stock in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 12 closing their positions.
36% less funds holding
Funds holding: 22 → 14 (-8)
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
91% less capital invested
Capital invested by funds: $1.26M → $117K (-$1.14M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$70.5K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$18.2K |
| 3 |
Millennium Management
New York
|
+$17.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.9K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.94K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$234K |
| 2 |
AC
Armistice Capital
New York
|
-$149K |
| 3 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$30.7K |
| 4 |
HF
HRT Financial
New York
|
-$15K |
| 5 |
State Street
Boston,
Massachusetts
|
-$15K |
VINC Hedge Fund Activity: Q1 2025 in Review
14 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q1 2025, worth a combined $117K — down 91% from $1.26M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of VINC and 4 opened new positions — a net loss of 8 holders — while 6 trimmed existing stakes and 2 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $70.5K. The largest seller was Rock Springs Capital Management, exiting entirely with an estimated $234K sold.
- 14 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q1 2025, down from 22 in Q4 2024.
- Funds reported $117K of Vincerx Pharma, Inc. Common Stock stock for Q1 2025, down 91% quarter-over-quarter.
- 4 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q1 2025 and 12 closed out, a net change of -8 holders.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q1 2025 was Citadel Advisors, an estimated $70.5K added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q1 2025 was Rock Springs Capital Management, an estimated $234K sold.
Based on aggregated 13F filings for Q1 2025.